| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9303051 | EMERGENT BIODEFENSE | Phosphonate ester derivatives and methods of synthesis thereof |
Aug, 2031
(7 years from now) | |
| US8962829 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10112909 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(10 years from now) | |
| US9371344 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(10 years from now) | |
| US10487061 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(10 years from now) | |
Tembexa is owned by Emergent Biodefense.
Tembexa contains Brincidofovir.
Tembexa has a total of 5 drug patents out of which 0 drug patents have expired.
Tembexa was authorised for market use on 04 June, 2021.
Tembexa is available in suspension;oral, tablet;oral dosage forms.
Tembexa can be used as method of treating human smallpox disease.
The generics of Tembexa are possible to be released after 10 October, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2024 |
| Orphan Drug Exclusivity(ODE-354) | Jun 04, 2028 |
Drugs and Companies using BRINCIDOFOVIR ingredient
Market Authorisation Date: 04 June, 2021
Treatment: Method of treating human smallpox disease
Dosage: TABLET;ORAL; SUSPENSION;ORAL
More Information on Dosage
TEMBEXA family patents
